China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Biopharmaceutical (Shanghai) Co., Ltd, has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study of BC007. The study will assess the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor efficacy of BC007 in patients with advanced solid tumors.
Drug Details
BC007 is a bispecific antibody (BsAb) targeting CLDN18.2 and CD47. The drug has a differential design for the affinity of its two targets. High affinity to CLDN18.2 allows BC007 to specifically bind to CLDN18.2-positive tumor cells, while lower affinity to CD47 enhances safety. It effectively blocks the CD47/SIRPα signaling pathway, releasing CD47-mediated immunosuppression in tumors. There are no similar products on the market globally.
Global Development
BC007 was approved for clinical trials in the US last month. Dragon Boat Pharmaceutical plans to advance its development in both markets.-Fineline Info & Tech
